Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2
Latest Information Update: 19 Sep 2023
At a glance
- Drugs COVID-19 vaccine-Castlevax (Primary) ; AZD 1222
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Avimex
Most Recent Events
- 13 Sep 2023 Status changed from active, no longer recruiting to completed.
- 19 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 07 Feb 2023 New trial record